Bank of New York Mellon Corp lessened its stake in Humana Inc. (NYSE:HUM) by 17.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,663,163 shares of the insurance provider’s stock after selling 352,978 shares during the period. Bank of New York Mellon Corp owned 1.15% of Humana worth $405,196,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of HUM. Creative Planning increased its stake in Humana by 0.3% in the 2nd quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after buying an additional 15 shares during the period. Aperio Group LLC grew its holdings in Humana by 24.0% during the 2nd quarter. Aperio Group LLC now owns 106,571 shares of the insurance provider’s stock worth $25,643,000 after acquiring an additional 20,614 shares in the last quarter. Hengehold Capital Management LLC bought a new position in Humana during the 2nd quarter worth about $209,000. Bedrijfstakpensioenfonds Voor DE Media PNO bought a new position in Humana during the 2nd quarter worth about $2,219,000. Finally, Sit Investment Associates Inc. grew its holdings in Humana by 0.3% during the 2nd quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock worth $2,892,000 after acquiring an additional 40 shares in the last quarter. 96.15% of the stock is currently owned by institutional investors.
Several brokerages have issued reports on HUM. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Credit Suisse Group began coverage on shares of Humana in a report on Thursday, November 2nd. They set a “neutral” rating and a $256.00 target price on the stock. BidaskClub upgraded shares of Humana from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. UBS AG reiterated a “neutral” rating and set a $250.00 target price (up from $237.00) on shares of Humana in a report on Wednesday, August 9th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $223.00 target price (up from $200.00) on shares of Humana in a report on Thursday, August 3rd. Thirteen investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $252.81.
In other Humana news, VP Timothy S. Huval sold 7,803 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the completion of the transaction, the vice president now directly owns 8,831 shares of the company’s stock, valued at approximately $2,279,634.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the transaction, the insider now directly owns 18,042 shares of the company’s stock, valued at $4,672,878. The disclosure for this sale can be found here. Insiders have sold a total of 20,660 shares of company stock valued at $5,319,600 over the last three months. 0.80% of the stock is currently owned by insiders.
Humana Inc. (NYSE HUM) traded down $6.28 during mid-day trading on Thursday, reaching $233.28. 1,618,700 shares of the company were exchanged, compared to its average volume of 1,380,572. Humana Inc. has a one year low of $186.25 and a one year high of $264.56. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35. The firm has a market cap of $34,223.56, a PE ratio of 20.44, a PEG ratio of 1.65 and a beta of 0.91.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. During the same period last year, the firm posted $3.18 EPS. Humana’s revenue for the quarter was down 3.0% compared to the same quarter last year. sell-side analysts anticipate that Humana Inc. will post 11.63 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date is Thursday, December 28th. Humana’s dividend payout ratio is presently 12.59%.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.